Icariin (3-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside)

Icariin is a prenylated flavonoid glycoside extracted from Epimedium species that acts as a phosphodiesterase-5 (PDE5) inhibitor. This compound modulates nitric oxide pathways through enhanced endothelial nitric oxide synthase (eNOS) activity, primarily supporting vascular and reproductive health.

Origin & History

Icariin is a flavonoid glycoside (3-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside) primarily extracted from Epimedium species, commonly known as horny goat weed. It is obtained through solvent extraction or purification from the aerial parts of the plant and belongs to the chemical class of prenylated flavonoids.

Historical & Cultural Context

Icariin from Epimedium species (horny goat weed) has been used in Traditional Chinese Medicine for many years, particularly for treating erectile dysfunction. It is also incorporated into formulations like Epimedium Total Flavonoid Capsule for osteoporosis symptom relief.

Health Benefits

• May support erectile function by modulating eNOS activity (preclinical evidence only)
• Shows potential for kidney protection in diabetic nephropathy models, reducing creatinine and blood urea nitrogen (animal studies only)
• May enhance testosterone production and sperm counts at 50-100 mg/kg doses (rat studies, no human trials)
• Demonstrated bone mineral density improvements in osteoporosis patients as part of Epimedium Total Flavonoid Capsule (limited human data)
• Exhibits antioxidant properties by increasing SOD/GPX and reducing lipid peroxidation at moderate doses (animal models)

How It Works

Icariin functions as a phosphodiesterase-5 (PDE5) inhibitor, increasing cyclic guanosine monophosphate (cGMP) levels and promoting nitric oxide-mediated vasodilation. The compound enhances endothelial nitric oxide synthase (eNOS) activity while modulating calcium channels and protein kinase pathways. Additionally, icariin demonstrates antioxidant properties by scavenging reactive oxygen species and activating nuclear factor erythroid 2-related factor 2 (Nrf2) pathways.

Scientific Research

Human clinical evidence for icariin alone is extremely limited, with only one phase 1 safety and pharmacokinetics trial (N=24 healthy adults) examining tolerability and cognitive effects over 24 hours. A 2021 protocol for a systematic review of RCTs on icariin for knee osteoarthritis was registered but no completed results are available. Most evidence comes from preclinical animal studies on diabetic nephropathy, reproductive function, and oxidative stress.

Clinical Summary

Current evidence for icariin is limited to preclinical animal studies and in vitro research, with no published human clinical trials available. Animal studies using 50-100 mg/kg doses showed improved erectile function markers and increased testosterone levels in rodent models. Diabetic nephropathy studies in rats demonstrated reduced creatinine and blood urea nitrogen levels with icariin supplementation. Human efficacy, optimal dosing, and safety profiles remain unestablished due to the absence of clinical trial data.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "carbohydrates": "Not applicable", "fats": "Not applicable", "fiber": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"icariin": "Concentration not specified; icariin is the primary bioactive compound in the compound", "bioavailability": "Icariin has low oral bioavailability due to poor absorption and rapid metabolism; often modified or combined with other compounds to enhance absorption"}}

Preparation & Dosage

Human dosing data is sparse; one phase 1 trial tested oral icariin in escalating doses (specific amounts not detailed). Animal studies used 20-150 mg/kg/day for diabetic nephropathy and 50-200 mg/kg for reproductive effects, with optimal results at 50-100 mg/kg. No standardized human equivalent doses have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-arginine, Panax ginseng, Tribulus terrestris, Zinc, Maca root

Safety & Interactions

Safety data for icariin in humans is extremely limited due to lack of clinical trials. Theoretical concerns include potential interactions with PDE5 inhibitor medications (sildenafil, tadalafil) due to similar mechanisms of action. Animal studies suggest possible mild gastrointestinal effects at high doses, though specific adverse events are poorly documented. Pregnancy and breastfeeding safety is unknown, and individuals with cardiovascular conditions should exercise caution due to the compound's vasodilatory effects.